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ABSTRACT 
Background: Dobutamine, a predominantly beta-adrenergic sympathomi- 
metic agent, is used for improving left ventricular (LV) systolic performance 
with different dosing regimens in patients with congestive heart failure (CHF). 
Myocardial performance index (MPI) is an indicator of LV global function that 
is correlated with LV end-diastolic pressure, and it is increased in CHE 
Objective: The purpose of this study was to examine the effects of a single, 
24-hour, low-dose, IV dobutamine infusion on LV systolic and diastolic function 
and on MPI in CHF as an indicator of LV global function, as well as the adverse 
effects (AEs) of the infusion. 
Methods: This prospective, nonrandomized study was conducted at the 
Department of Cardiology, Baskent University Hospital, Ankara, Turkey. Adult 
patients with LV ejection fraction (EF) <35%, sinus rhythm, and symptomatic 
CHF were treated using a standard protocol for at least 4 weeks. At the end of 
this period, patients with symptomatic CHF and EF <35% underwent echocardiog- 
raphy that included measuring isovolumic relaxation and contraction times 
(IRT and ICT, respectively) and LV ejection time (ET), and calculating LV MPI 
using the formula MPI = (IRT + ICT)/ET. Dobutamine 2.5 pg/kg-min was then 
infused intravenously for 24 hours. Echocardiography was repeated 24 hours 
later and values were compared with preinfusion data. Patients were observed 
and monitored for CHF symptoms and AEs for 24 hours. 
Results: Forty-three patients were enrolled in the study, and 31 (22 men, 
9 women; mean [SD] age, 67.55 [ 11.78] years) continued after the 4-week standard- 
treatment period. Mean (SD) heart rate (74.93 [20.15] vs 80.23 [13.74] bpm, 
respectively), systolic blood pressure (129.00 [19.23] vs 126.67 [23.79] mm Hg), 
and diastolic blood pressure (75.80 [11.26] vs 74.96 [8.30] mm Hg) were sta- 
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tistically similar before and after the infusion. The mean (SD) end-diastolic vol- 
ume was statistically similar to the preinfusion value (215.87 [76.74] vs 211.08 
[65.51] mL); however, the mean (SD) end-systolic volume was significantly re- 
duced (163.80 [63.86] vs 146.74 [53.12] mL; P = 0.01). Mean (SD) EF (25.33% 
[7.77%] vs 30.45% [7.63%]; P = 0.001) and stroke volume (SV) (54.92 [22.30] vs 
63.59 [23.91] mL; P= 0.04) increased significantly. The mean (SD) early:late dia- 
stolic flow velocity (E/A ratio)(1.58 [1.36] vs 1.65 [1.27]), IRT (107.03 [35.37] vs 
100.42 [34.32] ms), ICT (96.61 [34.27] vs 86.35 [44.80] ms), ET (240.65 [33.28] vs 
243.48 [33.54] ms), and MPI (0.81% [0.28%] vs 0.78% [0.31%]) did not change sig- 
nificantly after dobutamine infusion. No AEs were observed. 
¢ondus lons :  In this study of adult patients with symptomatic CHF, a single, 
24-hour, low-dose, IV dobutamine infusion (2.5 IJg/kg- min) was associated with 
decreased LV end-systolic volume and increased SV and EE However, LV dia- 
stolic function parameters, isovolumic time intervals, ET, and MPI were statisti- 
cally similar to preinfusion values. The infusion was well tolerated. (Curr Ther 
Res Clin Exp. 2005;66:35-44) Copyright © 2005 Excerpta Medica, Inc. 
Key words:  heart failure, dobutamine, myocardial performance index. 
INTIRODUa'ION 
Dobutamine, a predominantly beta-adrenergic sympathomimetic agent, is 
known to acutely increase left ventricular (LV) systolic function and to reduce 
symptoms in chronic and/or refractory congestive heart failure (CHF). Unfor- 
tunately, dobutamine has been associated with increased mortality when used 
in the long term, which limits its clinical use. 1,2 Based on a MEDLINE search 
(key terms: dobutamine, congestive heart failure, infusion, diastolic function, and 
acute; years: 1997-2005), few data concerning the acute effects of IV dobuta- 
mine infusion therapy on LV diastolic function are available. 3 Studies examining 
the acute differences in LV myocardial performance index (MPI) during dobuta- 
mine stress echocardiography (DSE) have shown that LV MPI can change acutely 
within minutes during dobutamine infusion periods. 4,S At the time of the litera- 
ture search, no data were available concerning the effects of a single, 24-hour, 
low-dose, IV dobutamine infusion used for therapeutic purposes on LV MPI, and 
the optimal infusion dose, frequency, and protocol for improving LV MPI were 
unknown. We hypothesized that such an infusion could be used to establish a 
stable plasma drug level and to create more prominent and continuous thera- 
peutic effects of dobutamine compared with short infusion times. The effects of 
dobutamine are also known to be dose dependent, and the minimum effective 
dose of the drug (2.5 pg/kg-min) is associated with few arthythmogenic ad- 
verse effects (AEs). 1 Thus, dobutamine would be an attractive therapeutic option 
if it had a beneficial effect on LV global function and MPI. 
The aim of this study was to examine the effects of a single, 24-hour, low-dose 
(2.5 IJg/kg" min) IV dobutamine infusion on LV systolic and diastolic function 
and on MPI as an indicator of global function, as well as the AEs of the infusion. 
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PATIEICll'S AND METHODS 
This prospective, nonrandomized study was conducted at the Department of 
Cardiology, Baskent University Hospital, Ankara, Turkey. The ethics committee 
at the university approved the investigaUonal protocol. Verbal informed con- 
sent was obtained from all eligible patients. 
Inclusion and Exclusion Criteria 
Patients aged 18 to 90 years presenting to the Department of Cardiology 
between December 2001 and June 2003 were prospectively enrolled. Inclusion 
criteria were ejection fraction (EF) <35%, sinus rhythm, and symptomatic CHF 
(defined as 3 of the following criteria: dyspnea on exertion, orthopnea, parox- 
ysmal nocturnal dyspnea, peripheral edema, and pulmonary venous congestion 
on chest radiography). 
Exclusion criteria were significant valvular egurgitation, uncontrolled hyper- 
tension (systolic/diastolic blood pressure, >160/>90 mm Hg), beta-blocker use, 
pregnancy, and poor echocardiographic visualization. 
Study Drug Administration 
All patients received a standard oral treatment regimen for CHF, which 
included digitalis (0.25 mg QD), [urosemide (40-80 mg QD), and enalapril (5- 
10 mg/d, in 2 divided doses), for 4 weeks. After 4 weeks, patients with rhythms 
other than sinus rhythm were withdrawn from the study, and patients with 
symptomatic CHF and EF <35% continued in the study. These patients were 
placed on bed rest in a coronary care unit and were observed and monitored 
for CHF symptoms and AEs for 24 hours. In addition to standard echocardiog- 
raphy, isovolumic relaxation and contraction times (IRT and ICT, respectively) 
and ejection time (ET) were measured, and LV MPI was calculated (equation fol- 
lows). Dobutamine 2.5 pg/kg- min was then infused intravenously for 24 hours. 
None of the medications were discontinued or changed uring the infusion peri- 
od. At the end of this single infusion, echocardiography was repeated and data 
were compared with preinfusion values. 
Echocardiographic Assessment 
Echocardiography was performed using the Acuson Sequoia Echo 256 sonog- 
raphy device (Acuson Corporation, Mountain View, California) and a 3.5-MHz 
transducer (model 3V2c, Acuson Corporation) with second-harmonic imaging 
at the left lateral decubitus position. Classic echocardiographic windows with 
electrocardiographic monitoring were used. All echocardiograms were video- 
taped for off-line analysis, which was performed by 2 investigators who were 
blinded to whether patients were being examined before or after dobutamine 
infusion. 
Two-dimensional Doppler echocardiography was performed according to 
the techniques described by the American Society of Echocardiography. ~,7The 
mean of 3 consecutive cardiac cycles was used for all echocardiographic vari- 
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ables. Measurements of LV systolic function were determined using the modi- 
fied Simpson's rule for biplanar imaging. G
Myocard ia l  Per fo rmance  Index  
The intervals used to derive the LV MPI are shown in the figure. Each in- 
terval was measured on 3 consecutive beats, and the mean was calculated. 
Interval a was the period from the end of the Doppler A (late diastolic flow) 
wave to the beginning of the E (early diastolic flow) wave of the next cardiac 
cycle. Interval a was obtained from the scan plane (apical 4-chamber view) for 
the left ventricle with a pulse-wave Doppler signal placed between the mitral 
valve leaflet ips. The LV ET 0nterval b for the left ventricle) was measured from 
the apical long-axis scan plane with a pulse-wave Doppler signal placed just 
inferior to the aortic valve at the LV outflow tract. The formula for calculating 
LV MPI was calculated as follows: 
MPI = (a - b)/b = (IRT + ICT)/ET 
The figure shows the equations used to derive the IRT and ICT of the left ventricle. 
V outflow 
! C ! 
F ' -  i 
J d i 
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IRT=c-d  
ICT = a -  b -  IRT 
a-  b ( IRT + ICT)  
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Figure. The myocardial performance index (MPI) is calculated from the following 
Dopp ler  intervals: a, the interval from cessation to onset of mitral valve 
inflow (ms); and b, the left ventricular ejection time (ET) (ms). Alternatively, 
the duration of mitral valve regurgitation is considered equal to interval a. 
Isovolumic relaxation time (IRT) is calculated using c, the interval between 
the peak of the R wave and the onset of mitral inflow, and d, the interval 
between the peak of the R wave and cessation of left ventricular outflow. 
The MPI is calculated as the sum of IRT and isovolumic contraction 
time OCT), divided by ET. ICT and IRT are derived as shown by the equa- 
tions in the bottom right corner of the figure. AW = atrioventricular valve; 




Data analysis was performed using SPSS version 9.0 (SPSS Inc., Chicago, 
lllinois). Continuous variables were expressed as mean (SD). Differences before 
and after infusion were assessed using the paired t test. P < 0.05 was considered 
statistically significant. 
RESULTS 
Of the patients who were screened for the study, 43 were enrolled, and 31 (22 men, 
9 women; mean [SD] age, 67.55 [ 11.78] years) continued after the 4-week standard- 
treatment period (Table I). Most of the patients were men with ischemic cardio- 
myopathy (n = 14). All 31 patients had dilated cardiomyopathy and New York Heart 
Association class III or IV disease (ie, marked or total limitation of physical activity). 
Before dobutamine infusion, the mean heart rate was normal (60-100 bpm), 
and the mean systolic and diastolic blood pressures were within the accepted 
ranges (<160/<90 mm Hg) (Table II). The mean EF was below normal (normal 
value, >50%) and the mean end-diastolic and end-systolic volumes were above 
normal (normal values, <120 and <50 mL, respectively). No significant diastolic 
dysfunction was identified in any of the patients, and the mean LV MPI was 
increased compared with previously accepted normal values. 
After 24-hour dobutamine infusion, all of the patients experienced improved 
symptoms, and no AEs were observed. Heart rate and systolic and diastolic blood 
pressures were statistically similar to preinfusion values. Mean end-systolic vol- 
ume decreased significantly (P= 0.01), and mean stroke volume (SV) and EF in- 
creased significantly (P= 0.04 and 0.001, respectively) compared with preinfusion 
values. Neither the diastolic function parameters nor MPI changed significantly. 
Table I. Baseline demographic and clinical characteristics of the study 
patients (N = 31). 
Characteristic Value 
Age, mean (SD), y 67.55 (11.78) 
Sex, no. (%) 
Male 22 (71.0) 
Female 9 (29.0) 
Type of dilated cardiomyopathy, no. (%) 
Ischemic 21 (67.7) 
Idiopathic 10 (32.3) 
NYHA disease class, no. (%) 
II1" 1 6 (51.6) 
IV t 15 (48.4) 
NYHA = New York Heart Association. 
*Marked limitation of physical activity. 
tTotal limitation of physical activity. 
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Table II. Echocardiographic findings in patients receiving dobutamine infusion (N = 31). 
Data are mean (SD). 
Variable Before Infusion After Infusion P 
HR, bpm 74.93 (20.15) 80.23 (I 3.74) NS 
SBP, mm Hg 129.00 (19.23) 126.67 (23.79) NS 
DBP, mm Hg 75.80 (I 1.26) 74.96 (8.30) NS 
EF, % 25.33 (7.77) 30.45 (7.63) 0.001 
End-diastolic volume, mL 215.87 (76.74) 211.08 (65.51) NS 
End-systolic volume, m/ 163.80 (63.86) 146.74 (53.12) 0.01 
SV, mE 54.92 (22.30) 63.59 (23.91) 0.04 
E, cm/sec 73.48 (28.57) 63.77 (23.74) NS 
A, cmlsec 66.00 (30.46) 56.93 (31.21) NS 
EIA ratio 1.58 (I .36) 1.65 (I .27) NS 
Deceleration time, ms 156.45 (73.49) 164.13 (85.31) NS 
IRT, ms 107.03 (35.37) 100.42 (34.32) NS 
ICT, ms 96.61 (34.27) 86.35 (44.80) NS 
ET, ms 240.65 (33.28) 243.48 (33.54) NS 
LV MPI, % 0.81 (0.28) 0.78 (0.31) NS 
HR = heart rate; SBP = systolic blood pressure; DBP = diastolic blood pressure; EF = ejection fraction; 
SV = stroke volume; [ = early diastolic flow velocity; A = late diastolic flow velocity; IRT = isovolumic 
relaxation time; ICT = isovolumic contraction time; ET = ejection time; LV MPl = left ventricular myocar- 
dial performance index. 
DISCUSSION 
MPI is an easily determined,  repeatable, quantitat ive chocardiographic  mea- 
surement  hat  can be used to determine LV global function. 8 More favorable 
function is found if the isovolumic phases  are short  and ejection t ime is long. 9 
In one study that compared  the MPI values of pat ients with di lated cardiomy- 
opathy  with those of healthy controls, 8the mean (SD) MPI value in healthy con- 
trols was 0.39 (0.05). MPI has been found to be correlated with LV end-diastol ic 
pressure 1° and invasive measurements  of it 0e, using cardiac catheterizat ion).  11 
MPI has been found to be independent of heart  rate and blood pressure.  4 MPI 
quantitat ively reflects ventr icular function in pat ients with complex ventr icular 
geometry  (ie, Ebstein's anomaly, LV aneurysm).  In the absence  of a geometr ic  
solution as the basis for the assessment  of ventr icular  systol ic function, this 
nongeometr ic  ndex is appeal ing for the assessment  of left and right ventr icular 
[unction. 12 Thus, it has clinical advantages in determining LV function com- 
pared with other  measurements .  8 
MPI has been found to be increased, whereas systol ic and diastolic function 
are poorer, in patients with CHF compared with healthy subjects, and MPI is asso- 
ciated with shortened ET and/or  increased IRT and ICT. 8 In a study of patients 
with dilated cardiomyopathy, the mean (SD) MPI was 0.59 (0.10). 13 MPI also has 
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been found to be valuable in determining the severity of CHF 14 and prognosis in 
dilated cardiomyopathy. 15,1G 
Clinical studies have shown that the acute, subacute, and long-term effects 
of dobutamine on cardiac function, symptoms, and clinical findings differ based 
on dose, infusion time, and the patient's condition. De Wolf et a117 found, in 
39 anthracycline-treated patients and 32 healthy controls, that improvement 
in EF paralleled progressively increasing doses of dobutamine in DSE (0.5- 
5.0 pg/kg-min at 10-minute intervals for 35 minutes). The improvement in EF was 
more prominent in healthy subjects. In another study, 4-hour IV infusion per week 
did not change resting LV function (pre-ejection period/ET and cardiac index [CI]), 
but exercise performance and clinical status improved. 18 Eryol et a119 found that 
IV dobutamine infusion (1-10 pg/kg-min for 72 h/mo), in combination with conven- 
tional therapy for CHF, created improved LV EE cardiac output, and CI, and caused 
lower pulmonary capillary wedge pressures in the first and second months of 
treatment, but these findings were reversed at 3 months. 
The acute effects of IV dobutamine infusion on LV MPI have been explored in 
a few studies that used DSE. Harada et al 4 studied 15 patients with surgically 
treated ventricular septal defect or Kawasaki disease and found that dobutamine 
(5 pg/kg.min for 15 minutes) increased ET and decreased IRT, ICT, and MPI on 
DSE. Parthenakis et al 5 studied 42 patients with dilated cardiomyopathy and 
found that dobutamine was associated with decreased IRT and ICT and hence 
improved MPI after peak dosage (10 pg/kg.min) was reached at the end of 12 min- 
utes of DSE. The findings of Norager et al 2° suggested that during low-dose DSE 
for 6 minutes, MPI worsens in patients with no LV functional reserve, and that 
the opposite is true for patients who have functional reserve and healthy con- 
trols. Gorgulu et a121 showed that low-dose dobutamine infusion (5 pg/kg.min for 
5 minutes) was associated with decreased MPI and increased IRT in a group of 
31 patients with normal LV systolic function. Elbl et a122 found that subclinical 
cardiac dysfunction with anthracycline chemotherapy was associated with high- 
er resting MPI values and a blunted MPI response during DSE (5-10 pg/kg.min). 
However, according to the literature search, no data were available concerning 
the effects of therapeutic dobutamine infusion on MPI. Theoretically, dobuta- 
mine might improve not only systolic but also diastolic function and may create 
a favorable ffect on global function as represented by MPI. However, the effects 
of dobutamine are related to the dose and infusion interval of the drug, beta- 
adrenergic receptor density, and myocardial properties. 
In the present study, we selected the smallest herapeutic dobutamine infu- 
sion dose, to eliminate arrhythmogenic AEs. The data showed that a single, 
24-hour, low-dose, IV dobutamine infusion decreased LV end-systolic volume and 
increased EF but did not improve IRT, ICT, ET, diastolic function parameters, or glo- 
bal function as represented by MPI. The decreased LV end-systolic volume found 
may be explained by improved myocardial contractility due to dobutamine treat- 
ment. As a result, SV is increased. However, the improvement in diastolic myocar- 
dial function is more difficult han improvement in systolic function. The difference 
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in myocardial calcium metabolism and a change in myocardial compliance are nec- 
essary to establish this improvement. Sometimes it is more complex to improve 
diastolic function than systolic [unction in severe CHE Capomolla et a123 reported 
that dobutamine was associated with improved LV systolic function but also im- 
paired diastolic function, and increased the severity of mitral valve regurgitation. 
Although some of the early studies howed that short infusions with progres- 
sively increasing doses of dobutamine during DSE improved systolic and dia- 
stolic parameters and global function as represented by MPI values, 4,5 later stud- 
ies suggest hat improved MPI is attributable to the functional reserve of the 
myocardium. 2°-22 Regardless, the results of both early and late studies 4,5,2°-22 
are due to higher doses of dobutamine used during DSE compared with the low 
dose used in our study. Obviously, different doses, infusion protocols, and myo- 
cardial conditions may cause different results. The results of the previously 
mentioned studies cannot be compared irectly with ours because our data are 
valid for only the dose, interval, and patient group used. Higher doses or longer 
infusion intervals may improve isovolumic time intervals, ET, and MPI, but may 
cause arrhythmogenic AEs and may limit the clinical use of dobutamine. 
Study Umitations 
Because MPI cannot be used to assess rhythms other than sinus rhythm, 24 the 
results of this study cannot be generalized toall patients with CHE Thus, the data 
are valid only for patients with CHF in sinus rhythm. The effect of increased or 
decreased preload on LV MPI is controversial. 25 All of the patients were receiving 
regular diuretic therapy, and patients with severe valvular egurgitations were ex- 
cluded. Thus, we conclude that preload was stable and did not affect our data. 
The present study was also limited because we were unable to measure iso- 
volumic time intervals and ET in the same cardiac cycle. The sample data were 
too small to generate confidence in the outcome. Furthermore, these data must 
be verified in a larger, randomized study to clarify the most effective drug dose, 
treatment duration, and frequency of infusion. 
Because our aim was to observe the adverse and echocardiographic effects 
during the study period, no follow-up period was studied, no data concerning 
long-term mortality were available, and a control group was not used. Instead, 
baseline (prein[usion) values were used as controls. 
These data are valid only in adult patients with ischemic and idiopathic dilated 
cardiomyopathy in sinus rhythm. MPI was not improved, but benefits on LV end- 
systolic volume, SV, and EF were observed. More investigations are needed to deter- 
mine the optimal dobutamine infusion dose and treatment duration that improves not 
only systolic function but also diastolic and global function (as represented by MPI'). 
CONCLUSIONS 
In this study of adult patients with symptomatic CHE a single, 24-hour, low- 
dose, IV dobutamine infusion (2.5 IJg/kg- min) was associated with decreased LV 
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end-systol ic vo lume and increased SV and EE However, diastolic function 
parameters ,  isovolumic t ime intervals, and LV ET and MPI were statistical ly sim- 
ilar to preinfusion values. The infusion was well tolerated. 
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